Windlas Biotech Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Windlas Biotech saw robust Q3 FY26 revenues of INR 233 Cr (+20% YoY) and 9M FY26 revenues of INR 666 Cr (+19% YoY), marking 12 consecutive quarters of record revenue. Excluding ESOPs, 9M EBITDA hit INR 89 Cr (13.3% margin) and PAT INR 60 Cr (9% margin). Key growth drivers were CDMO (+23% Q3), Trade Generics (+7% Q3), and Exports (+36% Q3). Plant 6 completion by FY26 end (INR 50-60 Cr capex) adds significant capacity. Management anticipates industry consolidation from stringent Schedule M. The company emphasizes capability building, disciplined execution, and strategic investments for long-term growth across all segments.